RESEARCH ARTICLE

Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with peglated interferon: A multicenter study

Kessarin Thanapirom1, Sirinporn Suksawatamnuay1, Wattana Sukeepaisarnjareon2, Tawesak Tanwandee3, Phunchai Charatcharoenwitthaya4, Satawat Thongsawat4, Apinya Leerapun5, Teerha Piratvisuth6, Rattana Boonsirichan7, Chaerermrat Bunchonntavakuil, Chaowalit Pattanasirigool8, Bubpha Pornthisarn9, Supot Tantipanichtheerakul10, Ekaew Sriprawath11, Woramon Jeamsripong12, Teeranan Sanpajit13, Yong Poovorawan14, Piyawat Komolmit1*

1 Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, 2 Division of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, 3 Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Bangkok, Thailand, 4 Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 5 Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, 6 Faculty of Medicine, Vajira Hospital, Bangkok, Thailand, 7 Faculty of Medicine, Rajavithi Hospital, Bangkok, Thailand, 8 Faculty of Medicine, Police General Hospital, Bangkok, Thailand, 9 Faculty of Medicine, Thammasat University Hospital, Bangkok, Thailand, 10 Faculty of Medicine, Bhumibol Adulyadej Hospital, Bangkok, Thailand, 11 Faculty of Medicine, Naresuan University, Phitsanulok, Thailand, 12 Faculty of Medicine, Buddhachinaraj Hospital, Phitsanulok, Thailand, 13 Phramongkutkla Hospital, Bangkok, Thailand, 14 Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

* pkomolmit@yahoo.co.uk

Abstract

Evidence of a role of vitamin D in the immune system is increasing. Low serum vitamin D is associated with increased hepatitis B virus replication. Genome-wide association study (GWAS) data has revealed a number of the single nucleotide polymorphisms (SNPs) within the vitamin D synthetic pathway that affect vitamin D functions. We aimed to determine the association between SNPs in the vitamin D gene cascade and response to peglated interferon (PegIFN) therapy in hepatitis B e-antigen (HBeAg)-positive patients. One hundred and eleven patients treated for 48 weeks with PegIFN-alfa 2a at 13 hospitals were retrospectively evaluated. Thirteen SNPs derived from vitamin D cascade-related genes, including DHCRR7 (rs12785878), CYP2B7 (rs10877012), CYP2R1 (rs2060793, rs12794714), GC (rs4588, rs7041, rs220202, rs2286279), and VDR (FokI, BsmI, Tru9I, ApaI, TaqI), were genotyped. Thirty-one patients (27.9%) seroconverted to HBeAg after 24 weeks of treatment. Multivariate analysis found pretreatment qHBsAg <10,000 IU/mL (OR = 7.73, 95% CI: 2.36–25.31, P = 0.001), CYP2R1 rs12794714 TT genotype (OR = 4.16, 95% CI: 1.07–16.25, P = 0.04), and baseline ALT >2 times the upper limit of normal (OR = 3.83, 95% CI: 1.31–11.22, P = 0.014) predicted sustained HBeAg seroconversion after completion of PegIFN...
treatment. HBV DNA during study period tended to be lower with the rs12794714 \textit{CYP2R1} TT than the non-TT genotype. The rs12794714 \textit{CYP2R1} polymorphism may be a useful pretreatment factor predictive of sustained HBeAg seroconversion after PegIFN therapy. This study provides evidence that not only vitamin D level but also genetic variation of \textit{CYP2R1} in the vitamin D cascade influences host immune response in chronic HBV infection.

\section*{Introduction}

Chronic hepatitis B (CHB) infection is a major global health problem, and more than 350 million persons are chronic carriers of hepatitis B virus (HBV) \cite{1, 2}. Currently available drugs include nucleos(t)ide analogs with high antiviral activity and HBV DNA suppression \cite{3}, but most patients will require life-long therapy \cite{4}. Finite duration of treatment with pegylated interferon (PegIFN) achieves an immune response to control HBV infection and induces a sustained response in 20–32\% of CHB patients \cite{5–7}. However, this therapy has frequent side effects in addition to a limited response. Therefore, identification of potential baseline predictors of durable off-treatment response is essential. In Hepatitis B early antigen (HBeAg)-positive patients, HBV genotype A or B, high baseline alanine aminotransferase (ALT) level, low pretreatment HBV-DNA level (<2.0×10^8 IU/mL), female sex, older age, basal core promoter and precore mutations of HBV, and absence of prior PegIFN therapy have been shown to predict a sustained response to PegIFN therapy \cite{8, 9}.

In addition to regulating calcium metabolism and bone homeostasis, vitamin D also has an important immunomodulatory effect on innate and adaptive immune responses \cite{10, 11}. Most vitamin D is synthesized from 7-dehydrocholesterol in sun-exposed skin; some is provided by the diet. The \textit{Dhcr7} gene encodes a reductase that catalyzes the conversion of 7-dehydrocholesterol to cholesterol. Dietary or cutaneous vitamin D undergoes two modification steps to become 1, 25-dihydroxyvitamin D [1,25(OH)\textsubscript{2}D], the active form of vitamin D. The first step is performed in the liver by \textit{Cyp2R1} and generates 25-hydroxyvitamin D [25(OH)D], which is the main circulatory form and is transported while bound to vitamin D binding protein (GC-globulin) \cite{12, 13}. In the second step, 25(OH)D is converted to 1,25(OH)\textsubscript{2}D in the kidney by 1α-hydroxylase. The \textit{Cyp27B1} gene encodes 1α-hydroxylase. 1,25(OH)\textsubscript{2}D exerts its biological functions by binding to and activating the vitamin D receptor (VDR) \cite{11}.

Low serum 25(OH)D is associated with various cancers, autoimmune, and infectious diseases \cite{14–16}, and vitamin D deficiency has been reported in chronic liver disease such as chronic viral hepatitis and nonalcoholic steatohepatitis \cite{17, 18}. In patients with CHB infection, low serum 25(OH)D has been associated with high levels of HBV replication and found to have an inverse relationship with serum HBV DNA level \cite{17}. In addition, HBeAg-positive patients were shown to have lower serum 25(OH)D levels than HBeAg-negative patients \cite{17}. Vitamin D deficiency has been related to adverse clinical outcomes in CHB-infected patients \cite{19} and low baseline vitamin D to ALT normalization after 48 weeks of therapy \cite{20}. A recent genome-wide association study (GWAS) and a systematic review found that variants of genes controlling vitamin D synthesis and transport influenced serum 25(OH)D levels. These included 7-dehydrocholesterol reductase-\textit{Dhcr7}, 1-α-hydroxylase-\textit{Cyp27B1}, Cytochrome P450, family 2, subfamily R, polypeptide 1-\textit{Cyp2R1}, vitamin D binding protein-\textit{Gc} and vitamin D receptor-\textit{Vdr} \cite{21–24}.

There are no data on the association of functional genetic variation of the vitamin D-related genes and outcome of PegIFN therapy in patients with HBeAg-positive CHB. This study
aimed to determine the association between the single nucleotide polymorphisms (SNPs) of vitamin D cascade and response to PegIFN therapy in patients with HBeAg-positive CHB infection.

**Materials and methods**

**Study participants**

We retrospectively analyzed 111 patients with HBeAg-positive CHB infection who were included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL) between January 2010 and December 2011. The patient sample was selected from 13 tertiary hospitals in Thailand, including King Chulalongkorn Memorial Hospital, Chulalongkorn University (Bangkok), Siriraj hospital, Mahidol University (Bangkok), Srinagarind hospital, Khon Kaen University (Khon Kaen), Maharaj Nakorn Chiang Mai hospital, Chiang Mai University (Chiang Mai), Songkla University hospital, Prince of Songkla University (Songkhla), Police hospital (Bangkok), Vajira Hospital, Navamindradhiraj University (Bangkok), Rajavithi hospital (Bangkok), Thammasat University hospital (Pathum Thani), Buddhachinaraj Hospital (Phitsanulok), Naresuan University hospital (Phitsanulok), Phramongkutklao hospital (Bangkok) and Bhumibol Adulyadej Hospital (Bangkok).

Eligible patients had been seropositive for HBsAg for more than 6 months before enrollment, seropositive for HBeAg, had a persistent serum ALT level above the upper limit of normal (ULN), and an HBV DNA level > 2,000 IU/mL. Patients previously treated with PegIFN or nucleos(t)ide analogs, with concomitant human immunodeficiency, hepatitis C or hepatitis D virus infection, decompensated cirrhosis, or contraindicated for PegIFN administration were excluded. Patients meeting the entry criteria were treated with subcutaneous PegIFN alfa-2a 180 μg/week (Pegasys, Roche Holding AG, Switzerland) for 48 weeks. Patient data was collected using standard case record forms. Demographic data were recorded as shown in Table 1. Serum ALT, HBV DNA, quantitative HBsAg (qHBsAg), HBeAg and anti-HBe were recorded at baseline, during treatment, and 24 weeks after completion of treatment. The study protocol, consent procedure was approved by the Institutional Review Boards of each study sites and conducted in compliance with principles of the Declaration of Helsinki under Good Clinical Practice. Individuals were informed of the study purpose and written consents were obtained.

| Table 1. Baseline characteristics of patients with HBeAg-positive chronic hepatitis B infection after 48 weeks of PegIFN therapy. |
|---------------------------------------------------------------|
| **No sustained HBeAg seroconversion** | **Sustained HBeAg seroconversion** | **p-value** |
| Male, n (%) | 59 (72.8%) | 20 (66.7%) | 0.64 |
| Age (years), mean ± SD | 39.1 ± 11.3 | 42.5 ± 11.2 | 0.13 |
| Body mass index (kg/m²), mean ± SD | 23.6 ± 3.6 | 24.0 ± 3.2 | 0.13 |
| HBV genotype, n (%) | | | |
| B | 12 (15.8%) | 1 (3.4%) | 0.09 |
| C | 63 (82.9%) | 28 (96.6%) | |
| D | 1 (1.3%) | 0 | 0.09 |
| Cirrhosis, n (%) | 6 (7.7%) | 3 (11.1%) | 0.13 |
| Pre-treatment HBV DNA (logIU/ml), mean ± SD | 7.3 ± 1.3 | 6.6 ± 1.5 | 0.006 |
| Pre-treatment HBsAg level (logIU/ml), mean ± SD | 3.9 ± 1.0 | 3.5 ± 0.7 | 0.004 |
| Pre-treatment ALT (U/L), mean ± SD | 95.7 ± 76.1 | 122.3 ± 91.8 | 0.04 |

PegIFN, pegylated interferon; HBV, hepatitis B virus; ALT, alanine aminotransferase; SD, standard deviation.

https://doi.org/10.1371/journal.pone.0173263.t001
obtained following the requirements of the local ethics committees. Informed consent was signed by the subject or the subject’s legally authorized representative.

Sustained HBeAg seroconversion was defined as negative for HBeAg and seropositive for anti-HBe 24 weeks after the end of therapy. Liver cirrhosis was determined by tissue histology, imaging, or measurement of liver stiffness. Loss of HBsAg was defined as undetectable HBsAg (i.e., HBsAg <0.05 IU/mL).

Laboratory measurement and characterization of SNPs

Thirteen functional SNPs in five genes, which have been reported the association with serum vitamin D from GWAS studies and systematic reviews were genotyped, including DHCR7 (rs12785878 G>T), CYP27B1 (rs10877012 C>A), CYP2R1 (rs2060793 T>C, rs12794714 C>T), GC (rs4588 C>A, rs7041 G>T, rs222020 G>A, rs2282679 A>C) and VDR (FokI rs228570 T>C, BsmI rs1544410 G>A, Tru9I rs757343 G>A, Apal rs7975232 G>T, TaqI rs731236 T>C)[21–24].

Human genomic DNA was extracted from 100 μl samples of peripheral blood mononuclear cells incubated with proteinase K in lysis buffer, followed by phenol–chloroform extraction, and ethanol precipitation. The pellet was dissolved in 50 μl sterile water and stored at −20˚C until further testing. For amplification, a PCR-specific primer set was designed. Aliquots containing 4 μl DNA were diluted 25 μl for PCR assays using Perfect Taq plus MasterMix (5 PRIME GmbH, Hamburg, Germany). The primer sequences and PCR conditions are summarized in S1 Table. Amplified DNA (10 μL) in a total volume of 20 μl was digested overnight with two units of restriction endonuclease (New England Biolabs, Hitchin, UK) using the buffers and temperatures recommended by the manufacturer. The resulting DNA fragments were separated electrophoretically on 2% agarose gels. The restriction fragment length polymorphism results were visualized under ultraviolet light after staining with ethidium bromide.

qHBsAg, HBeAg, anti-HBs, anti-HBe were assayed by electrochemiluminescence using an Elecsys (Roche Diagnostics, Indianapolis, IN, USA) or Architect (Abbott Diagnostics, Abbott Park, IL, USA) autoanalyzer. Serum HBV DNA level was quantified using the Roche Cobas Taqman assay, Roche Cobas Amplicor assay, or Abbott RealTime assay. HBV genotype was determined by the INNO-LiPA line probe assay (Innogenetics, Ghent, Belgium).

Statistical analysis

Statistical analysis was performed using SPSS software (version 22.0; IBM, New York city, NY, USA). The associations between variables were assessed using the Fisher’s exact test for categorical variables, and the Mann–Whitney test for continuous variables. Predictors of sustained HBeAg seroconversion were identified using multivariate logistic regression analysis. A P-value <0.05 was considered statistically significant for multiple logistic regression analysis. While Bonferroni Correction was used to adjust p-value for factors, which were compared multiple times including qHBsAg and HBV DNA. The assumption of Hardy-Weinberg equilibrium was assessed for all SNPs using χ² test.

Results

Patient characteristics and prevalence of the studied SNPs

A total of 111 patients with HBeAg-positive CHB infection were enrolled; 71.2% (n = 79) were men, and the mean age was 39.9 ± 11.3 years. All patients were Thai; nine (8.6%) had compensated cirrhosis, and 91 (86.7%) were infected with HBV genotype C. Median pretreatment HBV DNA was 7.64 log IU/mL, qHBsAg was 3.93 log IU/ml, and ALT 75 was IU/ml. Table 1
Table 2. Genotype frequencies of DHCR7, CYP27B1, CYP2R1, GC and VDR in HBeAg-positive chronic hepatitis B patients treated with PegIFN for 48 weeks.

| Genotype | All patients (n = 111) | Non Sustained HBeAg seroconversion (n = 80) | Sustained HBeAg seroconversion (n = 31) | Odds ratio (95% CI) | p-value |
|----------|------------------------|--------------------------------------------|----------------------------------------|---------------------|---------|
| **DHCR7 rs12785878** |                          |                                            |                                        |                     |         |
| G>T      |                        |                                            |                                        |                     |         |
| GG       | 49 (44.1%)             | 35 (43.2%)                                 | 14 (46.7%)                             | 1.15(0.50–2.67)      | 0.83    |
| GT       | 51 (46.0%)             | 40 (49.4%)                                 | 11 (36.7%)                             |                     |         |
| TT       | 11 (9.9%)              | 6 (7.4%)                                   | 5 (16.6%)                              |                     |         |
| **CYP27B1 rs10877012** |                          |                                            |                                        |                     |         |
| C>A      |                        |                                            |                                        |                     |         |
| CC       | 24 (21.6%)             | 18 (22.2%)                                 | 6 (20.0%)                              | 0.87 (0.31–2.47)      | 1.00    |
| CA       | 52 (46.9%)             | 37 (45.7%)                                 | 15 (50.0%)                             |                     |         |
| AA       | 35 (31.5%)             | 26 (32.1%)                                 | 9 (30.0%)                              |                     |         |
| **CYP2R1 rs2060793** |                          |                                            |                                        |                     |         |
| T>C      |                        |                                            |                                        |                     |         |
| TT       | 12 (10.8%)             | 11 (13.6%)                                 | 1 (3.3%)                               | 0.22 (0.03–1.78)      | 0.17    |
| TC       | 39 (35.1%)             | 29 (35.8%)                                 | 10 (33.4%)                             |                     |         |
| CC       | 60 (54.1%)             | 41 (50.6%)                                 | 19 (63.3%)                             |                     |         |
| **CYP2R1 rs12794714** |                          |                                            |                                        |                     |         |
| C>T      |                        |                                            |                                        |                     |         |
| CC       | 44 (39.6%)             | 36 (44.5%)                                 | 8 (26.7%)                              |                     |         |
| CT       | 51 (46.0%)             | 38 (46.9%)                                 | 13 (43.3%)                             |                     |         |
| TT       | 16 (14.4%)             | 7 (8.6%)                                   | 9 (30.0%)                              | 4.53 (1.51–13.61)     | 0.01    |
| **GC rs4588 C>A** |                          |                                            |                                        |                     |         |
| CC       | 55 (49.5%)             | 41 (50.6%)                                 | 14 (46.7%)                             | 0.85 (0.37–1.98)      | 0.83    |
| CA       | 50 (45.1%)             | 34 (42.0%)                                 | 16 (53.3%)                             |                     |         |
| AA       | 6 (5.4%)               | 6 (7.4%)                                   | 0                                      |                     |         |
| **GC rs7041 G>T** |                          |                                            |                                        |                     |         |
| GG       | 6 (5.4%)               | 5 (6.2%)                                   | 1 (3.3%)                               | 0.52 (0.06–4.68)      | 1.00    |
| GT       | 56 (50.5%)             | 39 (48.1%)                                 | 17 (56.7%)                             |                     |         |
| TT       | 49 (44.1%)             | 37 (45.7%)                                 | 12 (40.0%)                             |                     |         |
| **GC rs222020 G>A** |                          |                                            |                                        |                     |         |
| GG       | 29 (26.1%)             | 21 (25.9%)                                 | 8 (26.7%)                              | 1.04 (0.40–2.68)      | 1.00    |
| GA       | 47 (42.4%)             | 35 (43.2%)                                 | 12 (40.0%)                             |                     |         |
| AA       | 35 (31.5%)             | 25 (30.9%)                                 | 10 (33.3%)                             |                     |         |
| **GC rs2282679 A>C** |                          |                                            |                                        |                     |         |
| AA       | 59 (53.2%)             | 43 (53.1%)                                 | 16 (53.3%)                             | 1.01 (0.44–2.34)      | 1.00    |
| AC       | 46 (41.4%)             | 32 (39.5%)                                 | 14 (46.7%)                             |                     |         |
| CC       | 6 (5.4%)               | 6 (7.4%)                                   | 0                                      |                     |         |
| **VDR FokI rs2228570 T>C** |                          |                                            |                                        |                     |         |
| TT       | 26 (23.4%)             | 22 (27.2%)                                 | 4 (13.3%)                              | 0.41 (0.13–1.32)      | 0.21    |
| TC       | 61 (55.0%)             | 42 (51.8%)                                 | 19 (63.3%)                             |                     |         |
| CC       | 24 (21.6%)             | 17 (21.0%)                                 | 7 (23.4%)                              |                     |         |
| **VDR BsmI rs1544410 G>A** |                          |                                            |                                        |                     |         |
| GG       | 98 (88.3%)             | 72 (88.9%)                                 | 26 (86.7%)                             | 0.81 (0.23–2.87)      | 0.75    |
| GA       | 12 (10.8%)             | 9 (11.1%)                                  | 3 (10.0%)                              |                     |         |
| AA       | 1 (0.9%)               | 0                                          | 1 (3.3%)                               |                     |         |

(Continued)
shows the baseline characteristics of patients with and without HBeAg seroconversion at 24 weeks after treatment completion.

The genotypic distribution of the SNPs in this study is shown in Table 2. Genotypic distribution of all alleles were in Hardy–Weinberg equilibrium equation (P > 0.05).

**Treatment response and HBV genotype**

When the treatment ended, 53 patients (54.1%) had HBV DNA < 2,000 IU/ml and ALT normalization occurred in 67 (60.4%). At 24 weeks after PegIFN discontinuation, 30 (27.0%) achieved sustained HBeAg seroconversion, eight (7.5%) cleared HBsAg, and 67 (60.4%) had ALT normalization. The result of HBV genotype was available in 105 patients (94.6%). Table 3 shows the patient responses at the end of treatment and at 24 weeks of follow-up classified according to HBV genotype. Sustained HBeAg seroconversion was obtained in 30.8% (n = 28) of patients with the C genotype and 7.1% (n = 1) of those with the non-C genotype. At 24 weeks of follow-up, 75 patients (68.6%) had HBV DNA < 2,000 IU/ml, 28 (23.3%) had ALT normalization, and 6 (5.4%) had HBsAg loss. The p-values are shown in Table 3.

**Table 2. (Continued)**

| SNP                  | All patients (n = 111) | Non Sustained HBeAg seroconversion (n = 80) | Sustained HBeAg seroconversion (n = 31) | Odds ratio (95% CI) | p-value |
|----------------------|------------------------|--------------------------------------------|----------------------------------------|---------------------|---------|
| VDR Tru9 rs757343 G>A|                        |                                            |                                        |                     |         |
| GG                   | 59 (53.2%)             | 47 (58.0%)                                 | 12 (40.0%)                             | 0.48 (0.21–1.13)    | 0.09    |
| GA                   | 49 (44.1%)             | 32 (39.5%)                                 | 17 (56.7%)                             |                     |         |
| AA                   | 3 (2.7%)               | 2 (2.5%)                                   | 1 (3.3%)                               |                     |         |
| VDR ApaI rs7975232 G>T|                       |                                            |                                        |                     |         |
| GG                   | 53 (47.8%)             | 43 (53.1%)                                 | 10 (33.3%)                             | 0.44 (0.18–1.06)    | 0.08    |
| GT                   | 48 (43.2%)             | 32 (39.5%)                                 | 16 (53.4%)                             |                     |         |
| TT                   | 10 (9.0%)              | 6 (7.4%)                                   | 4 (13.3%)                              |                     |         |
| VDR TaqI rs731236 T>C|                       |                                            |                                        |                     |         |
| TT                   | 102 (91.9%)            | 75 (92.6)                                  | 27 (90.0%)                             | 0.72 (0.17–3.08)    | 0.70    |
| TC                   | 9 (8.1%)               | 6 (7.4%)                                   | 3 (10.0%)                              |                     |         |
| CC                   | 0                      | 0                                          | 0                                       |                     |         |

PegIFN, pegylated interferon.

https://doi.org/10.1371/journal.pone.0173263.t002

**Table 3. Outcomes in patients with HBeAg-positive CHB infection stratified by HBV genotype after completing 24 weeks of PegIFN treatment.**

| At end-of-treatment | Total (n = 111) | HBV genotype C (n = 91) | HBV non-genotype C (n = 14) | p-value |
|---------------------|-----------------|-------------------------|-----------------------------|---------|
| HBV DNA < 2,000 IU/ml| 53 (54.1%)      | 42 (53.2%)              | 7 (50.0%)                   | 0.83    |
| HBeAg seroconversion| 26 (25.2%)      | 26 (31.0%)              | 0                           | 0.01    |
| HBsAg loss          | 5 (5.1%)        | 5 (6.1%)                | 0                           | 0.36    |
| ALT normalization    | 67 (60.4%)      | 54 (59.3%)              | 12 (64.3%)                  | 0.06    |

| At 24 weeks of follow-up | Total (n = 111) | HBV genotype C (n = 91) | HBV non-genotype C (n = 14) | p-value |
|--------------------------|-----------------|-------------------------|-----------------------------|---------|
| HBV DNA < 2,000 IU/ml    | 42 (41.2%)      | 36 (43.4%)              | 5 (35.7%)                   | 0.13    |
| HBeAg seroconversion     | 30 (27%)        | 28 (30.8%)              | 1 (7.1%)                    | 0.07    |
| HBsAg loss               | 8 (7.5%)        | 6 (6.8%)                | 1 (7.1%)                    | 0.96    |
| ALT normalization        | 67 (60.4%)      | 54 (59.3%)              | 12 (85.7%)                  | 0.06    |

PegIFN, pegylated interferon; HBV, hepatitis B virus; CHB, chronic hepatitis B; ALT, alanine aminotransferase.

https://doi.org/10.1371/journal.pone.0173263.t003
weeks after PegIFN discontinuation, 6.8% of patients with the C genotype and 7.1% of those with the non-C genotype were HBsAg negative, and ALT normalization was achieved by 59.3%, 85.7%, respectively. Treatment outcomes were not different between patients with HBV genotype C and non-C at end-of-treatment and 24 weeks of follow-up, except genotype C had more HBeAg seroconversion at end-of-treatment.

Treatment response in patients with DHCR7 (rs12785878), CYP27B1 (rs10877012), CYP2R1 (rs2060793, rs12794714), GC (rs4588, rs7041, rs222020, rs2282679), and VDR (FokI, BsmI, Tru9I, Apal, TaqI) gene polymorphisms

The overall genotype frequencies of the SNPs in vitamin D pathway genes observed in all patients and in HBeAg-positive patients with and without sustained HBeAg seroconversion are summarized in Table 2. The CYP2R1 rs12794714 TT genotype was associated with a higher rate of sustained HBeAg seroconversion than non-TT genotype (56.2% vs. 22.1%, \( P = 0.01 \)). Patients who achieved HBeAg seroconversion had a higher T-allele frequency of CYP2R1 rs12794714 than patients who did not achieve that endpoint (51.6% vs. 32.1%, \( P = 0.007 \)). Loss of HBeAg was observed in nine patients with the CYP2R1 rs12794714 TT genotype (56.2%) vs. 28 patients with the non-TT genotype (30.1%). The remaining SNPs of the DHCR7 (rs12785878), CYP27B1 (rs10877012), CYP2R1 (rs2060793), GC (rs4588, rs7041, rs222020, rs2282679), VDR (FokI, BsmI, Tru9I, Apal, TaqI) genes were not related to HBeAg seroconversion after therapy. The genetic variations of the SNPs in the vitamin D pathway genes were not associated with seroclearance of HBsAg, or ALT normalization at 24 weeks after PegIFN treatment.

Prevalence of CYP2R1 rs12794714 and association with sustained HBeAg seroconversion among HBV genotypes

The genotype frequencies of CYP2R1 rs12794714 CC, CT, and TT were 39.6%, 44.0%, and 16.5%, respectively, in HBV genotype C and 42.9%, 57.1%, and 0%, in HBV non-genotype C patients. The CYP2R1 rs12794714 TT genotype was strongly associated with HBeAg seroconversion in HBV genotype C patients, where 60.0% with the TT genotype achieved sustained HBeAg seroconversion compared with 25.0% of those with the non-TT genotype (\( P = 0.007 \)). The CYP2R1 rs12794714 polymorphism was not associated with HBeAg seroconversion after HBV treatment in non-genotype C patients.

Pretreatment predictors of sustained HBeAg seroconversion

Following Univariate analysis, potentially confounding variables with \( P \leq 0.1 \), including baseline HBV DNA, qHBsAg, ALT, HBV genotype, CYP2R1 rs12794714 TT, VDR ApaI GG, and VDR Tru9I GG genotypes were evaluated by multivariate analysis. Pretreatment qHBsAg < 10,000 IU/mL (OR = 7.73, 95% CI: 2.36–25.31, \( P = 0.001 \)), CYP2R1 rs12794714 TT genotype (OR = 4.16, 95% CI: 1.07–16.25, \( P = 0.04 \)), and baseline ALT > 2 times the upper limit of normal (OR = 3.83, 95% CI: 1.31–11.22, \( P = 0.014 \)) were independent predictors of sustained HBeAg seroconversion after PegIFN therapy in HBeAg-positive patients with CHB infection.

Association of HBV DNA and qHBsAg kinetics during and after treatment with CYP2R1 rs12794714 genotype

The kinetics of HBV DNA and qHBsAg during and after PegIFN therapy in patients stratified by CYP2R1 rs12794714 TT and non-TT genotype are shown in Fig 1. Mean HBV DNA (log
IU/ml) tended to be lower in patients with CYP2R1 rs12794714 TT than in those with non-TT genotype at baseline and during PegIFN therapy. Also, after discontinuation of PegIFN treatment, HBV DNA there was a trend toward continuing suppression TT patients compared with non-TT genotype patients. Mean qHBsAg during and after therapy tended to be lower in TT compared with non-TT CYP2R1 rs12794714 genotype, but the differences did not reach significance.

Discussion

In this study, we investigated the possible association between functional genetic polymorphisms in the vitamin D metabolic pathway—DHCR7, CYP27B1, CYP2R1, GC, and VDR—and sustained treatment response in patients with HBeAg-positive CHB infection treated with PegIFN for 48 weeks. The main finding is that polymorphism of rs12794714 of the CYP2R1
gene independently predicted sustained HBeAg seroconversion in HBeAg-positive patients after completing PegIFN treatment. This suggests that the PegIFN-influenced immune response may be partially determined by host genetic factors in the vitamin D cascade. PegIFN on its own led to a sustained off-treatment response in approximately one-third of the patients, and was therefore a potent treatment option for patients with HBeAg-positive CHB. Several host and viral factors have been proposed to predict response to PegIFN therapy [8, 25].

Recently, the evidence that vitamin D plays important role in immunomodulation has become stronger [10, 11], and host immune status has been shown to be key for both persistent CHB infection and PegIFN treatment responses [26, 27]. A high prevalence of vitamin D deficiency and insufficiency, ranging from 81–93%, has been seen in patients with CHB infection [17, 20], and serum 25(OH)D concentration has been seen to be significantly lower than in healthy individuals living in the same geographic region [15, 28]. Low serum vitamin D levels have been associated with high levels of HBV replication and poor clinical outcomes, including cirrhotic complications, hepatocellular carcinoma, and death [17, 19]. Previous studies showed that genetic variation of the vitamin D metabolic pathway, including CYP27B1-1260 rs10877012 and VDR FokI rs2228570, was associated with sustained virological response to PegIFN therapy in patients with chronic hepatitis C infection [29, 30]. However, in patients with CHB infection, polymorphism of the CYP27B1 SNP rs4646536 promoter was related to PegIFN response in HBeAg-negative patients [31]. In this patient series, the CYP2R1 rs12794714 TT genotype predicted sustained HBeAg seroconversion after PegIFN treatment. This novel host genetic factor might be useful for predicting treatment response to PegIFN in HBeAg-positive patients. The mechanism was not clearly identified, but we found that patients with the CYP2R1 rs12794714 TT genotype tended to have lower HBV DNA from baseline to 24 weeks posttreatment follow-up compared with those with a non-TT genotype. In addition, the CYP2R1 rs12794714 TT genotype had trend to be associated with lower HBV DNA and qHBsAg during and after PegIFN therapy. This genotype variant might be reflective of an active host immune response.

The CYP2R1 gene, located on chromosome 11p15.2, contains five exons, includes about 15.5 kb, and encodes vitamin D 25-hydroxylase. The rs12794714 SNP of CYP2R1 was significantly associated with serum 25(OH)D in Han children in northeast China and in Singapore [32, 33]. There have been no prior data of CYP2R1 rs12794714 genotypic frequencies in Thai populations, but the frequencies were 39.6% for the CC, 48.7% for the CT, and 11.7% for the TT genotypes in middle-aged and elderly Singapore Chinese [33]. This study indicated that not only serum vitamin D level but also the CYP2R1 rs12794714 variant was related to HBV replication, but that it also predicted response to PegIFN treatment in patients with HBeAg-positive CHB. None of the other 12 SNPs of the vitamin D genes that were evaluated predicted a sustained response to PegIFN therapy.

In addition to CYP2R1 rs12794714 polymorphism, this study demonstrated that baseline qHBsAg < 10,000 IU/mL and ALT levels > 2 times the upper limit of normal were also pre-treatment factors for predicting HBeAg seroconversion in Thai HBeAg-positive patients treated with PegIFN. These findings are similar to those reported by Fan et al. showing that baseline anti-HBc, HBV DNA, and ALT were predictors of HBeAg seroconversion in HBeAg-positive patients treated with PegIFN or nucleos(t)ide analogues [34]. In term of selection these cut-off for baseline qHBsAg and ALT level to perform multivariate analysis were based on previous studies [35, 36]. Our study had several limitations. First, we did not evaluate the effect of baseline serum 25(OH)D level because it is influenced by several potentially confounding variables including exposure to UV sunlight, malabsorption, reduced dietary intake of the vitamin, and decreased hepatic hydroxylation resulting from chronic liver disease [25]. Also, we wanted to demonstrate the association of key functional polymorphisms of vitamin D
genes with treatment response, which might not be affected by other factors. Second, this study included the small number of HBeAg-positive patients and had limited period of follow-up, which might reduce the precise conclusion and hardly prove that there were no association between other studied SNPs and HBeAg seroconversion. Further studies with large number of patients are needed to clarify the influence of vitamin D related gene polymorphisms on the PegIFN treatment.

Conclusions
The CYP2R1 rs12794714 TT genotype may be associated with sustained HBeAg seroconversion and may be a promising baseline predictor of PegIFN response, which help to identify HBeAg-positive CHB patients suitable for PegIFN therapy.

Supporting information
S1 Table. The primer sequences and polymerase chain reaction conditions of 13 studied single nucleotide polymorphisms.

(DOC)

Acknowledgments
We would like to thank the staff of the Division of Gastroenterology, Department of Medicine, Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University and Thai Association for the Study of the Liver (THASL) for their technical and administrative assistance.

Author Contributions

Conceptualization: KT SS YP PK.

Data curation: KT WS TT PC S. Tantipanichtheerakul AL TP RB CP BP S. Thongsawat ES WJ TS PK.

Formal analysis: KT SS WS PC YP PK.

Funding acquisition: TT TP PK.

Investigation: KT WS TT PC S. Tantipanichtheerakul AL TP RB CP BP S. Thongsawat ES WJ TS PK.

Methodology: KT SS YP PK.

Project administration: PK.

Resources: KT WS TT PC S. Tantipanichtheerakul AL TP RB CP BP S. Thongsawat ES WJ TS PK.

Software: KT.

Supervision: PK.

Validation: KT SS WS PC YP PK.

Visualization: KT SS WS PC YP PK.

Writing – original draft: KT SS WS PC YP PK.

Writing – review & editing: PC YP PK.
References

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359(14):1486–500. Epub 2008/10/04. https://doi.org/10.1056/NEJMoa0801644 PMID: 18832247

2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373(9663):582–92. Epub 2009/02/17. https://doi.org/10.1016/S0140-6736(09)60207-5 PMID: 19217933

3. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010; 51(1):73–80. Epub 2009/12/10. https://doi.org/10.1002/hep.22246 PMID: 19998272

4. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011; 8(5):275–84. Epub 2011/03/23. https://doi.org/10.1038/nrgastro.2011.33 PMID: 21423660

5. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26):2682–95. Epub 2005/07/01. https://doi.org/10.1056/NEJMoa043470 PMID: 15987917

6. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008; 135(2):459–67. Epub 2008/07/01. https://doi.org/10.1053/j.gastro.2008.05.031 PMID: 18585385

7. Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 2010; 105(8):1762–9. Epub 2010/05/13. https://doi.org/10.1038/ajg.2010.186 PMID: 20461068

8. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009; 137(6):2002–9. Epub 2009/09/10. https://doi.org/10.1053/j.gastro.2009.08.061 PMID: 19737568

9. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013; 57(3):934–43. Epub 2012/11/01. https://doi.org/10.1002/hep.26121 PMID: 23112104

10. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol. 2010; 11(4):344–9. Epub 2010/03/09. https://doi.org/10.1038/ni.1851 PMID: 20208539

11. White JH. Vitamin D metabolism and signaling in the immune system. Reviews in endocrine & metabolic disorders. 2012; 13(1):21–9.

12. Shinkyo R, Sakaki T, Kamakura M, Ohta M, Inouye K. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun. 2004; 324(1):451–7. Epub 2004/10/07. https://doi.org/10.1016/j.bbrc.2004.09.073 PMID: 15465040

13. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012; 56(5):1641–50. Epub 2012/05/23. https://doi.org/10.1002/hep.25848 PMID: 22610885

14. Raghuwanshi A, Joshi SS, Christakos S. Vitamin D and multiple sclerosis. J Cell Biochem. 2008; 105(2):338–43. Epub 2008/07/26. PubMed Central PMCID: PMC2859312. https://doi.org/10.1002/jcb.21858 PMID: 18655192

15. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008; 37(1):113–9. Epub 2008/02/05. https://doi.org/10.1093/ije/dym247 PMID: 18245055

16. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7(9):684–700. Epub 2007/08/28. https://doi.org/10.1038/nrc2196 PMID: 17721433

17. Farnik H, Bojunga J, Berger A, Allwinn R, Waidmann O, Kronenberger B, et al. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology. 2013; 58(4):1270–6. https://doi.org/10.1002/hep.26488 PMID: 23703797

18. Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology. 2013; 58(3):1166–74. Epub 2013/03/19. https://doi.org/10.1002/hep.26390 PMID: 23504808

19. Wong GL, Chan HL, Chan HY, Tse CH, Chim AM, Lo AO, et al. Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. Clinical gastroenterology and hepatology: the official
McGrath JJ, Saha S, Burne TH, Eyles DW. A systematic review of the association between common
Bu FX, Armas L, Lappe J, Zhou Y, Gao G, Wang HW, et al. Comprehensive association analysis of
Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic deter-
Cheng L, Sun X, Tan S, Tan W, Dan Y, Zhou Y, et al. Effect of HLA-DP and IL28B gene polymorphisms
24. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Human molecular genetics. 2010; 19(13):2739–45. Epub 2010/04/27. PubMed Central PMCID: PMC2883344. https://doi.org/10.1039/hmg-diq155 PMID: 2041845
25. Cheng L, Sun X, Tan S, Tan W, Dan Y, Zhou Y, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res. 2014; 44(9):1000–7. Epub 2013/12/05. https://doi.org/10.1111/hepr.12284 PMID: 24298935
26. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005; 41(4):771–8. Epub 2005/03/26. https://doi.org/10.1002/hep.20649 PMID: 15791617
27. Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, et al. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology. 2001; 33(1):295–300. Epub 2000/12/22. https://doi.org/10.1053/hep.2001.21147 PMID: 11124848
28. Reusch J, Ackermann H, Badenhoop K. Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res. 2009; 41(5):402–7. Epub 2009/02/26. https://doi.org/10.1055/s-0028-1128131 PMID: 19241329
29. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of hepatology. 2011; 54(5):887–93. Epub 2010/12/15. https://doi.org/10.1016/j.jhep.2010.08.036 PMID: 21145801
30. Garcia-Martin E, Agundez JA, Maestro ML, Suarez A, Vidaurreta M, Martinez C, et al. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS one. 2013; 8(9):e74764. Epub 2013/09/28. PubMed Central PMCID: PMC3779247. https://doi.org/10.1371/journal.pone.0074764 PMID: 24073221
31. Boglione L, Cusato J, De Nicolò A, Cartil G, Di Perri G, D’Avolio A. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. Journal of viral hepatitis. 2015; 22(3):318–27. https://doi.org/10.1111/jvhl.12288 PMID: 25060765
32. Zhang Y, Wang X, Liu Y, Qu H, Qu S, Wang W, et al. The GC, CYP2R1 and DHCR7 genes are associated with vitamin D levels in northeastern Han Chinese children. Swiss Med Wkly. 2012; 142:w13636. Epub 2012/07/18. https://doi.org/10.4444/smwr.2012.13636 PMID: 22801813
33. Robien K, Butler LM, Wang R, Beckman KB, Walek D, Koh WP, et al. Genetic and environmental predictors of serum 25-hydroxyvitamin D concentrations among middle-aged and elderly Chinese in Singapore. Br J Nutr. 2013; 109(3):493–502. Epub 2012/05/16. PubMed Central PMCID: PMC3442149. https://doi.org/10.1017/S0007114512001675 PMID: 22583563
34. Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016; 65(2):313–20. Epub 2015/01/15. PubMed Central PMCID: PMC4752655. https://doi.org/10.1136/gutjnl-2014-308546 PMID: 25586058
35. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Alimentary pharmacology & therapeutics. 2010; 32(11–12):1323–31.
36. Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatology international. 2008; 2(1):102–10. PubMed Central PMCID: PMC2716864. https://doi.org/10.1007/s12072-007-9022-5 PMID: 19669285